91ÑÇÉ«´«Ã½

News

A decoy may be the key to developing a vaccine against a deadly bioweapon

New research shows how Venezuelan equine encephalitis virus attaches to cells, paving the way for a vaccine
Amanda Rossillo
By Amanda Rossillo
April 11, 2021

Though the international prohibited biological warfare and the development of bioweapons in 1975, the knowledge gained from previous research and testing didn't just disappear. This, combined with a the agreement and subsequent , has prompted some nations to attempt to develop vaccines against known bioweapons as a precaution.

Mask-445x297.jpg
Photo by Scott Rodgerson on Unsplash

One such bioweapon is (VEEV), which is naturally found as far north as Florida and south through Mexico, Central America, and South America. It is transmitted to humans through mosquitos or through from infected horses and donkeys. VEEV targets the nervous system, and can be fatal if it enters the brain. Though VEEV is not usually deadly in humans, it causes symptoms in , including fever, severe headache, vomiting, and diarrhea, and may cause neurological complications.

VEEV was by the United States and Soviet Union during the Cold War. It was manufactured as an , designed to cause severe symptoms that would not only weaken the opposing military, but also require valuable resources to contain and treat. 

Though it has never actually been used in warfare, VEEV has that make it a powerful potential bioweapon. like dengue and it requires specialized tests to diagnose. It is relatively easy to produce and store, and there are multiple dangerous strains. To make matters worse, it's also extremely infectious — at least 20 staff became ill when in 1959 in a laboratory stairwell in the former Soviet Union. 

...researchers created a "decoy" protein and injected it into living mice in an effort to trick the virus

Most VEEV strains are under highly restricted access in the United States, and there is no vaccine available for the public; a live-virus vaccine does exist for the and at-risk laboratory personnel. However, this vaccine often causes adverse side effects, requires multiple booster shots, and may even be able to once inside the body.

, scientists used CRISPR gene editing technology to determine how VEEV enters cells. Because they could not access the most dangerous strains of VEEV, they created a hybrid virus using genes from a milder VEEV strain and a related virus. This hybrid infected cells in the same way as the most dangerous VEEV strains while being safe to handle.

They then deleted genes from mice brain cells and exposed the cells to the modified version of VEEV. They found that when a little-studied gene called Ldlrad3 was removed, the virus could not enter these cells. Conversely, when Ldlrad3 was added to different types of cells that are usually naturally resistant to VEEV infection, VEEV was able to enter. Notably, when study co-author William Klimstra using human cells and a dangerous, restricted strain of VEEV, they observed the same results.

Ldlrad3 codes for a protein that's found on the surface of neurons, and the researchers believe it to be the main "handle" that the virus uses to attach to the cell (in the same way that of SARS-CoV-2 into cells). However, since this gene is naturally present in our bodies, it can't just be deleted to prevent infection.

Donkey-890x593.jpg
Photo by on
VEEV is spread to humans by mosquitoes as well as aerosols from horses, donkeys, and mules

To circumvent this issue, these researchers created a "decoy" protein and injected it into living mice in an effort to trick the virus. The idea is that a VEEV virus attaches to a decoy, which blocks it from latching on to the protein LDLRAD3 (made by the gene Ldlrad3), much like how having your hands full keeps you from picking up something new. This would mean that VEEV viruses would be unable to enter the cells, preventing infection. For this experiment, the team was able to access one of the restricted VEEV strains.

The mice were injected with the decoy protein six hours before and 24 hours after exposure to VEEV. All of the mice who were infected with VEEV without the decoy protein died, while all of those who received the decoy survived. Even when VEEV was injected directly into their brains, eight of the ten mice who received the decoy survived.

While the decoy hasn't yet been tested in humans or other susceptible animals, researchers hope that it could be developed into a vaccine to be used during outbreaks.

Outbreaks are particularly devastating in regions that rely on equines (horses, donkeys, and mules) for agriculture and transportation. Not only do equines commonly spread the disease to humans, but they are also much from the virus. Though some equine VEEV vaccines have been used in the past, they unknowingly contained the activated, infectious virus and are thought to have actually prior to 1970. A new and improved vaccine that could be given to both farm animals and humans could slow the spread of the virus, minimizing the health and economic impacts of outbreaks.

These same regions are also home to the mosquito vectors of VEEV. These mosquitos prefer warm, wet habitats, and more recent outbreaks have been recorded after . As global warming accelerates, VEEV-carrying mosquitos may into North America, putting even more people at risk of contracting this pathogen even in the absence of an act of war. 

VEEV is just one of many potentially lethal bioweapons without a satisfactory vaccine. The vaccine for anthrax must be administered in over the course of 18 months, with booster shots needed each year. Vaccines for botulism, caused by one of , also exist, but their actual effectiveness is unknown and .

Though more testing is needed to evaluate the decoy protein's potential as a new vaccine for VEEV, its preliminary success may pave the way for improved vaccines for other bioweapons in the future.

And while VEEV is (hopefully) not an imminent security threat to the United States, we may sleep a little easier knowing that a vaccine is in the works to prevent another pandemic.

Enjoy reading 91ÑÇÉ«´«Ã½ Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Amanda Rossillo
Amanda Rossillo

Amanda Rossillo is an evolutionary anthropology PhD student at Duke University. Her work on human evolution focuses on Homo naledi, a mysterious extinct human relative found in South Africa.

Get the latest from 91ÑÇÉ«´«Ã½ Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Targeting toxins to treat whooping cough
Journal News

Targeting toxins to treat whooping cough

May 1, 2025

Scientists find that liver protein inhibits of pertussis toxin, offering a potential new treatment for bacterial respiratory disease. Read more about this recent study from the Journal of Biological Chemistry.

Elusive zebrafish enzyme in lipid secretion
Journal News

Elusive zebrafish enzyme in lipid secretion

May 1, 2025

Scientists discover that triacylglycerol synthesis enzyme drives lipoproteins secretion rather than lipid droplet storage. Read more about this recent study from the Journal of Biological Chemistry.

Scientists identify pan-cancer biomarkers
Journal News

Scientists identify pan-cancer biomarkers

April 30, 2025

Researchers analyze protein and RNA data across 13 cancer types to find similarities that could improve cancer staging, prognosis and treatment strategies. Read about this recent article published in Molecular & Cellular Proteomics.

New mass spectrometry tool accurately identifies bacteria
Journal News

New mass spectrometry tool accurately identifies bacteria

April 30, 2025

Scientists develop a software tool to categorize microbe species and antibiotic resistance markers to aid clinical and environmental research. Read about this recent article published in Molecular & Cellular Proteomics.

New tool matches microbial and metabolic metaproteomic data
Journal News

New tool matches microbial and metabolic metaproteomic data

April 30, 2025

Scientists develop a bioinformatics program that maps omics data to metabolic pathways. Read about this recent article published in Molecular & Cellular Proteomics

Meet Paul Shapiro
Interview

Meet Paul Shapiro

April 29, 2025

Learn how the JBC associate editor went from milking cows on a dairy farm to analyzing kinases in the lab.